NYR.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

DCF fair valuemodel estimate

Intrinsic value

$0.04

Price

$0.72

Implied downside

-94%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NYR.AXNyrada Inc.	$0.74	+2.07%	$180M	—
ACW.AXActinogen Medical Limited	$0.06	+1.75%	$216M	—
AHC.AXAustco Healthcare Limited	$0.27	+1.89%	$101M	—
AVH.AXAVITA Medical, Inc.	$2.82	+0.71%	$350M	—
BIO.AXBiome Australia Limited	$0.37	+4.23%	$84M	—
EMV.AXEMVision Medical Devices Ltd	$1.73	+2.37%	$160M	—
ILA.AXIsland Pharmaceuticals Limited	$0.44	+2.33%	$130M	—

Source: Financial Modeling Prep · peers by sector/industry

Nyrada Inc.

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

www.nyrada.com

Employees: 4,000
IPO / List date: Jan 15, 2020
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds NYR.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in NYR.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NYR.AX yet.